Rethinking Early Airway Clearence Therapies
Public ClinicalTrials.gov record NCT07696338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The REACT trial consists of two parallel, randomized studies; the Hypertonic Saline Study and the Dornase Alfa Study. Health outcomes among people with cystic fibrosis (CF) have been steadily improving, most recently with the advent of highly effective modulator therapy (HEMT). While therapies like hypertonic saline (HS) and dornase alfa (DA) improved outcomes in the past, they are often burdensome. Now that almost 90% of the North American CF population is being treated with elexacaftor/tezacaftor/ivacaftor (ETI) or vanzacaftor/tezacaftor/deutivacaftor (VTD), this trial will evaluate whether these newer treatments make daily HS or DA unnecessary. The trial begins with a 6-week run-in period where participants continue ETI or VTD but stop using HS and DA. Eligible participants are then assigned to either the HS Study or the DA Study for one year. Within those groups, they are randomized to either daily use of HS or DA or as needed use only during respiratory illnesses. The study aims to find out if lung health is similar between children and teens taking HEMT who use HS or DA treatments daily and those who use HS or DA treatments only when they are sick.
Study identification
- NCT ID
- NCT07696338
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 405 participants
Conditions and interventions
Conditions
Interventions
- As-needed hypertonic saline (HS) Other
- Twice daily hypertonic saline (HS) Other
- As-needed dornase alfa (DA) Other
- Daily dornase alfa (DA) Other
Other
Eligibility (public fields only)
- Age range
- 3 Years to 16 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2026 (Estimated)
- Primary completion
- Feb 28, 2030 (Estimated)
- Completion
- Feb 28, 2030 (Estimated)
- Last update posted
- Jul 10, 2026
2026 – 2030
United States locations
- U.S. sites
- 36
- U.S. states
- 24
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Children's Hospital Alabama, University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Tucson Cystic Fibrosis Center | Tucson | Arizona | 85724 | — |
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| CHOC Children's Hospital | Orange | California | 92868 | — |
| Stanford University Medical Center | Palo Alto | California | 94025 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| All Children's Hospital | St. Petersburg | Florida | 33701 | — |
| Children's Healthcare of Atlanta and Emory University | Atlanta | Georgia | 30322 | — |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | — |
| Riley Hospital for Children | Indianapolis | Indiana | 46202 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| John Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| University of Michigan, Michigan Medicine | Ann Arbor | Michigan | 48109 | — |
| Children's Hospitals and Clinics of Minnesota | Minneapolis | Minnesota | 55404 | — |
| The Minnesota Cystic Fibrosis Center | Minneapolis | Minnesota | 55455 | — |
| Children's Mercy Kansas City | Kansas City | Missouri | 64108 | — |
| St. Louis Children's Hospital | St Louis | Missouri | 63110 | — |
| University of Rochester Medical Center Strong Memorial | Rochester | New York | 14642 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| Dayton Children's Hospital | Dayton | Ohio | 45404 | — |
| Oregon Health & Sciences University | Portland | Oregon | 97239 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Texas Southwestern / Children's Health | Dallas | Texas | 75207 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| University of Virginia | Charlottesville | Virginia | 22904 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
| Providence Medical Group, Cystic Fibrosis Clinic - Pediatrics | Spokane | Washington | 99204 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
| Children's Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07696338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07696338 live on ClinicalTrials.gov.